MultiHance Dosage
Generic name: gadobenate dimeglumine 529mg in 1mL
Dosage form: injection, solution
Drug class: Magnetic resonance imaging contrast media
Medically reviewed by Drugs.com. Last updated on Mar 16, 2025.
2.1 Dosing and Imaging Instructions
2.1.1 MRI of the CNS
In adults and in pediatric patients over 2 years of age, the recommended dose of MultiHance for MRI of the CNS is 0.2 mL/kg (0.1 mmol/kg) administered as a rapid bolus intravenous injection. In pediatric patients below 2 years of age, the recommended dosage range is 0.1 to 0.2 mL/kg administered as a rapid bolus intravenous injection. To ensure complete injection of the contrast medium, follow the injection with a saline flush of at least 5 mL. Imaging of the CNS can be performed starting immediately after the bolus injection of MultiHance.
2.1.2 MRA of Renal and Aorto-ilio-femoral Vessels
For MRA examination, the recommended dose is 0.2 mL/kg (0.1 mmol/kg) administered as a rapid bolus intravenous injection followed by at least 20 mL saline flush either manually or using an automatic injector system. Start imaging immediately after the administration of MultiHance, with scan delay calculated by test bolus or automatic bolus detection technique. If an automatic contrast detection pulse sequence is not used for bolus timing, then a test bolus injection of 1-2 mL of MultiHance should be used to calculate the appropriate scan delay.
2.2 Dosing Table
*For pediatric patients less than 2 years of age, one-half of the per kg dose may be used. | ||
TABLE 1: WEIGHT-BASED DOSING VOLUMES FOR: CNS IMAGING (ADULTS AND PEDIATRICS ≥2 YEARS OF AGE*) AND MRA IMAGING (ADULTS ONLY) |
||
0.1mM/kg dose | ||
Kilograms (Kg) | Pounds (lb) | Volume, Milliliters (mL) |
2.5 | 5.5 | 0.5 |
5 | 11 | 1.0 |
10 | 22 | 2.0 |
15 | 33 | 3.0 |
20 | 44 | 4.0 |
25 | 55 | 5.0 |
30 | 66 | 6.0 |
35 | 77 | 7.0 |
40 | 88 | 8.0 |
45 | 99 | 9.0 |
50 | 110 | 10.0 |
55 | 121 | 11.0 |
60 | 132 | 12.0 |
65 | 143 | 13.0 |
70 | 154 | 14.0 |
75 | 165 | 15.0 |
80 | 176 | 16.0 |
85 | 187 | 17.0 |
90 | 198 | 18.0 |
95 | 209 | 19.0 |
100 | 220 | 20.0 |
105 | 231 | 21.0 |
110 | 242 | 22.0 |
115 | 253 | 23.0 |
120 | 264 | 24.0 |
125 | 275 | 25.0 |
130 | 286 | 26.0 |
135 | 297 | 27.0 |
140 | 308 | 28.0 |
145 | 319 | 29.0 |
150 | 330 | 30.0 |
2.3 Administration
Inspect the MultiHance vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present. Draw MultiHance into a syringe and inject using sterile technique.
Do not mix intravenous medications or parenteral nutrition solutions with MultiHance. Do not administer other medications in the same intravenous line with MultiHance.
2.4 Directions for Proper Use of MultiHance Multipack
The pharmacy bulk package is used as a multiple dose container with an appropriate transfer device to fill empty syringes.
MultiHance Multipack injection should be drawn into the syringe and administered using sterile technique. Unused portions of the drug must be discarded.
When MultiHance Multipack injection is to be injected using plastic disposable syringes, the agent should be drawn into the syringe and used immediately.
- The transferring of MultiHance (gadobenate dimeglumine) injection from the Pharmacy Bulk Package should be performed in a suitable work area, such as a laminar flow hood, utilizing aseptic technique.
- The container closure may be penetrated only one time, utilizing a suitable transfer device. Once the pharmacy bulk package is punctured, it should not be removed from the aseptic work area during the entire period of use.
- The withdrawal of container contents should be accomplished without delay. However, should this not be possible, a maximum time of 8 hours from initial closure entry is permitted to complete fluid transfer operation. Any unused MultiHance Multipack injection must be discarded 8 hours after initial puncture of the bulk package.
- Temperature of container after the closure has been entered should not exceed 25°C (77°F).
More about Multihance (gadobenate dimeglumine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- During pregnancy
- Drug class: magnetic resonance imaging contrast media
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.